The affordability of lecanemab, an amyloid-targeting therapy for Alzheimer's disease: an EADC-EC viewpoint by Linus Jönsson, Anders Wimo, Ron Handels, Gunilla Johansson, Mercè Boada, Sebastiaan Engelborghs, Lutz Frölich, Frank Jessen, Patrick Gavin Kehoe, Milica Kramberger, Alexandre de Mendonςa, Pierre Jean Ousset, Nikolaos Scarmeas, Pieter Jelle Visser, Gunhild Waldemar, Bengt Winblad

Get full text